Abstract. T follicular helper (Tfh) cells are known to support effector B cells and enhance autoimmunity; however, the association between the Tfh cells and B cells in ankylosing spondylitis (AS) is unclear. The aim of the present study was to measure the frequency of circulating cluster of differentiation (CD)4 + C-X-C chemokine receptor type 5 (CXCR5) + Tfh cells and B cell subtypes in peripheral blood from patients with AS, and evaluate the correlation of these factors. Percentages of peripheral blood circulating CD4 + CXCR5 + Tfh cells and B cell subtypes were measured via flow cytometry and the disease activity of individual patients was measured using the Bath AS Disease Activity Index (BASDAI). The potential association among these measures was analyzed via Spearman ' + CD38 + antibody-secreting B cells may participate in the pathogenesis of AS because of their distinct functions. As such, levels of cTfh and B cell subtypes may be a useful biomarker for the evaluation of disease activity in patients with AS.
Introduction
Ankylosing spondylitis (AS) is a chronic, progressive autoimmune disease that, theoretically, affects the axial and sacroiliac joints. More importantly, the majority of patients with AS eventually develop spine malformations, leading to functional incapacity (1) . Although, the pathogenesis of AS remains unknown, an increasing amount of research has been performed to elucidate it.
Previous studies have reported elevated percentages of peripheral blood T helper (Th)1, Th17 and Th22 cells, and decreased percentages of regulatory T cells in patients with AS (2-4). However, to the best of our knowledge, there have been only two studies regarding a novel, distinct subgroup of cluster of differentiation (CD)4 + T cells, known as follicular helper T cells (Tfh), in patients with AS (5, 6) . A number of previous studies have demonstrated that aberrant expression of circulating (c)Tfhs may mediate the development of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis and Sjogren's syndrome (7) (8) (9) (10) . Tfhs are known as specialized providers of help to B cells and persistently express C-X-C chemokine receptor type 5 (CXCR5), which drives Tfh migration into B cell follicles in response to the specific ligand CXCL13, which is expressed by follicular dendritic cells (11 
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interact with B cell surface ligands to promote the formation of germinal centers (GC), the differentiation of B cells and antibody production (13, 14) . In addition, other previous studies have reported increased percentages of B cells and high levels of autoantibodies in patients with AS (15, 16) . However, very few studies have focused on the phenotypic and functional status of B cells in different disease activities of AS. Several reports have demonstrated that the abnormal distribution of B cell subtypes may participate in the pathogenesis of autoimmune diseases, such as RA, SLE and IgA nephropathy (17) (18) (19) . A previous study of primary Sjogren's syndrome (8) has reported that abnormal increases of CD4 + CXCR5 + Tfh cells and B cell subsets in the salivary gland were significantly correlated with serum antinuclear antibody titers. A further study (20) revealed higher percentages of activated B and Tfh cells in patients with RA as well as regulation of B cell activation via active Tfh cells in the process of RA.
As such, the aim of the present study was to investigate changes in the distribution of B cell subtypes and whether Tfh is associated with the distribution of B cell subtypes in patients with AS. The frequency of cTfhs and different stages of differentiated B cells were investigated in 65 patients with AS as well as in 20 gender and age-matched healthy participants. The present findings suggest that certain subtypes of cTfh cells and B cells may participate in the pathogenesis of AS due to their distinct functions, and the percentages of cTfhs and B cell subtypes may be useful as a valuable measure for evaluating disease activity in patients with AS.
Materials and methods

Patients and controls.
A total of 65 patients with AS were recruited sequentially at the outpatient clinic of Guizhou Medical University Hospital (Guiyang, China) from September 2014 to October 2015. All patients fulfilled the 1984 modified New York criteria (21) , which is the criterion for diagnosing AS. A further 20 healthy age-and sex-matched individuals with no history of inflammatory or autoimmune diseases were recruited during the same period as healthy controls (HC). Patients with AS were excluded if they had any other chronic inflammatory and autoimmune disorders such as diabetes, multiple sclerosis or inflammatory bowel disease, or if they were currently receiving treatment with non-steroidal anti-inflammatory drugs, steroids, or other immunosuppressants. The disease activity of individual patients was measured using the Bath AS Disease Activity Index (BASDAI) (22) . The scores for each criterion ranged from 0-10, with high activity defined as a BASDAI score ≥4 and low activity defined as a BASDAI score <4. All patients provided written informed consent prior to their inclusion in the present study and the experimental protocol was approved by the institutional ethics committee of Guizhou Medical University Hospital. The characteristics of the study subjects are summarized in Table I Peripheral venous blood in duplicate was incubated with 12 µg/ml allophycocyanin (APC)-cyanine (CY)7-anti-CD4 (cat no. 341115; BD Biosciences), peridinin-chlorophyll-protein complex (PERCP)-CY5.5-anti-CXCR5 (cat no. 562781; BD Pharmingen, San Diego, CA, USA), 0.5 mg/ml FITC-anti-PD-1 (FITC-anti-CD279; cat no. 561035; BD Pharmingen; BD Biosciences) and 0.2 mg/ml PE-anti-ICOS (PE-anti-CD278; cat no. 552146; BD Pharmingen; BD Biosciences) antibodies in the dark at room temperature for 15 min. Control cells were also from patients with AS and were incubated with 12 µg/ml APC-CY7-anti-CD4, 25 µg/ml PERCP-CY5.5-anti-immunoglobulin G (IgG)1 (cat no. 347202; BD Biosciences), 50 µg/ml FITC-anti-IgG (cat. no. 349041; BD Biosciences) and 50 µg/ml PE-anti-IgG1 (cat. no. 349043; BD Bioscience) in the dark at room temperature for 15 min, which is a negative control of flow analysis. Controls were isotyped, which helped eliminate non-specific fluorescent interference in flow analysis. In addition, peripheral blood in duplicate was stained with 0.05 mg/ml APC-anti-CD19 (cat. no. 340437; BD Biosciences), 8 µg/ml FITC-anti-CD27 (cat. no. 340424; BD Biosciences), 25 µg/ml PE-CY7-anti-CD38 (cat. no. 335790; BD Biosciences) or isotype-matched controls (BD Bioscience) at room temperature for 15 min. Following lysis of erythrocytes with hemolysin and washing with PBS, white blood cells were subjected to FACS Canto II flow cytometry analysis using a FACSDiva software version 6.1.3 (BD Biosciences).
Analysis of cytokine production. Peripheral blood in duplicate was stimulated with 50 ng/ml phorbol myristate acetate (PMA; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 1 µg/ml ionomycin (Sigma-Aldrich; Merck KGaA) with 10% fetal calf serum (Zhejiang Tianhang Biotechnology Co., Ltd., Zhejiang, China) in RPMI 1640 medium (Boster Biological Technology, Pleasanton, CA, USA) at 37˚C in an incubator with 5% CO 2 for 1.5 h and subsequently cultured for a further 4.5 h in the presence of GlogiStop (cat. no. 554724; BD Biosciences) at 37˚C. As the expression of CD4 epitope would be decreased following the stimulation of PMA and ionomycin (23) , CD3 + CD8 -T was used to represent CD3 + CD4 + T cells. The stimulated cells were incubated with 100 µg/ml FITC-anti-CD3 (cat. no. 349201; BD Biosciences), 50 µg/ml PE-CY7-anti-CD8 (cat. no. 335822; BD Biosciences) and 3 µg/ml PE-anti-CD69 (cat. no. 341652; BD Pharmingen; BD Bioscineces) antibodies in the dark at room temperature for 15 min. Control cells were incubated with 100 µg/ml FITC-anti-CD3, 50 µg/ml PE-CY7-anti-CD8 and 50 µg/ml PE-anti-IgG1 (cat. no. 349043; BD Biosciences) antibodies in the dark at room temperature for 15 min. Statistical analysis. Statistic analyses were performed using SPSS (version 20.0; IBM Corp., Armonk, NY, USA). Normally distributed data are expressed as the mean ± standard deviation, whereas skewed data are presented as the median. Kolmogorov-Smirnov test was used to assess the distribution of the data. In addition, Levene's test was used to evaluate the homogeneity of variances. The significance of the difference between multiple groups was performed using one-way analysis of variance with a post-hoc Student-Newman-Keuls test and the significance of difference between two groups was evaluated with two-tailed Student's t-test. Spearman correlation coefficient or Pearson correlation coefficient with two-tailed P-values were determined in the analysis of correlations. Two-sided P<0.05 was considered to indicate a statistically significant difference.
Results
Increased percentages of CD4
+ CXCR5 + cTfh cells in patients with AS. To investigate the potential role of Tfh cells and their surface molecules in the development of AS, the frequency of peripheral blood CD4 + T and CD4 + CXCR5 + cTfh cells were characterized with flow cytometry analysis (Fig. 1A) . It was demonstrated that there was a decreased frequency of CD4 + T cells in patients with AS compared with HC (P<0.01; Fig. 1B Fig. 1C-E) . Furthermore, the percentage of CD4 + CXCR5
+ cTfh was significantly elevated in the high activity AS group (BASDAI score ≥4; n=41) compared with that in the low activity AS group (BASDAI score <4; n=24; P=0.001) and in HC (n=20; P<0.001; Fig. 1C To determine whether the lymphocytes were activated, the expression of CD69 in stimulated T lymphocytes was measured using flow cytometry, as presented in Fig. 2A Fig. 2B and D) . This suggests that different cellular sources of IL-21 are associated with the development of AS in this cellular population.
Aberrant distribution of peripheral blood B cell subtypes in patients with AS. As presented in Fig. 3 , the distribution of B cell subtypes was also measured using flow cytometry. The percentages of CD19 + CD27 high plasmablasts and CD19 + CD38 + antibody-secreting B cells in patients with AS were significantly higher than those in HC (P<0.001 for all; Fig. 3C and F) . There was no significant difference in the frequency of CD19 + B cells, CD19 + CD27 -naïve B cells and CD19 + CD27 + memory B cells between patients with AS and HC (Fig. 3B, D and E) . The percentages of CD19 + CD38 + antibody-secreting B cells and CD19 + CD27 -naïve B cells were also significantly increased in the high activity AS group (n=24) compared with the low activity AS group (n=22) and HC groups (P<0.05; Fig. 3C and D) . In contrast, the frequency of CD19 + CD27 + memory B cells was significantly decreased in the high activity patients with AS, compared with the low activity AS group (P<0.05; Fig. 3E) . Notably, the percentage of CD19 + CD38 + antibody-secreting B cells was positively correlated with the BASDAI values in patients with AS (r= 0.329, P= 0.007; Fig. 3G ). However, there was no significant correlation between the BASDAI values and Fig. 4C and D) . However, there was no significant correlation between percentages of other cTfh cell phenotypes + T cells producing IL-21 were compared between patients with AS (n=54; some patients with AS failed the test and were not included in statistical analysis) and HC (n=20). IL, interleukin; CD, cluster of differentiation; CXCR5, C-X-C chemokine receptor type 5; NS, no significant differences; HC, healthy controls; AS, ankylosing spondylitis; SSC, side scatter data; FSC, forward scatter data. and class switch recombination (24, 35 (17, 18) . In the present study, it was demonstrated that the percentages of CD19 + CD27 high plasmablasts and CD19
+ CD38 + antibody-secreting B cells were increased in patients with AS, relative to HC, although there was no significant difference in the frequency of CD19 + B cells, CD19 + CD27 -naïve B cells, and CD19 + CD27 + memory B cells between patients with AS and HC. These results suggest that, following antigen stimulation, the distribution of B cell subtypes was changed and the proportions of the plasmablasts and antibody-secreting B cells were highly increased compared with other B cell subtypes in patients with AS. This was likely due to a higher presence of plasmablasts and antibody-secreting B cells following the high differentiation of bone marrow stem cells in order to produce more antibodies against a foreign antigen. The present findings were partially consistent with a previous study by Lin et al (15) (39) . This may explain why antibody-secreting B cell levels markedly increased and more naive B cells were released by bone marrow. Furthermore, this may be the underlying reason for the significant positive correlations between cTfh and B subtypes. These findings support the hypothesis that Tfh cells may regulate the distribution of B cell subtypes via different functional molecules; however, further research is required to elucidate the precise molecular and immunological mechanism.
In conclusion, the present findings suggest that the percentages of cTfh cells and activated B cell subtypes are significantly increased and positively correlated with disease activity in patients with AS, and the percentage of cTfh cells is positively correlated with particular B cell subtypes. The limitations of the present study, which must be considered when interpreting these results, include the relatively small sample size and the lack of cell culture experiments on cTfh cells and B cells. Further studies are required to address the relationship between circulating Tfh cells and B cell subtypes in patients with AS.
